Affimed (NASDAQ:AFMD) Receives $13.50 Average Price Target from Brokerages

Affimed (NASDAQ:AFMD) has been assigned a consensus recommendation of “Moderate Buy” from the five ratings firms that are presently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $13.50.

AFMD has been the topic of several analyst reports. Stifel Nicolaus decreased their target price on shares of Affimed from $5.00 to $4.00 and set a “hold” rating on the stock in a research note on Friday, November 15th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Affimed in a research note on Tuesday, November 19th. Wells Fargo & Company cut their target price on Affimed from $20.00 to $15.00 and set an “overweight” rating on the stock in a research note on Thursday, December 12th. Finally, HC Wainwright restated a “buy” rating and set a $10.00 price target on shares of Affimed in a report on Tuesday, December 10th.

Affimed Stock Down 6.3 %

Shares of Affimed stock opened at $1.18 on Tuesday. The company has a quick ratio of 1.93, a current ratio of 1.93 and a debt-to-equity ratio of 0.13. Affimed has a one year low of $1.15 and a one year high of $8.95. The business’s 50 day simple moving average is $2.99 and its two-hundred day simple moving average is $4.12.

Institutional Trading of Affimed

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Jane Street Group LLC bought a new position in shares of Affimed in the 3rd quarter worth about $44,000. Point72 Asset Management L.P. grew its holdings in Affimed by 4.6% in the third quarter. Point72 Asset Management L.P. now owns 342,856 shares of the biopharmaceutical company’s stock worth $1,152,000 after purchasing an additional 15,108 shares during the period. FMR LLC increased its stake in shares of Affimed by 30.0% during the third quarter. FMR LLC now owns 17,696 shares of the biopharmaceutical company’s stock valued at $59,000 after purchasing an additional 4,086 shares in the last quarter. Intellectus Partners LLC lifted its holdings in shares of Affimed by 12.2% during the third quarter. Intellectus Partners LLC now owns 94,361 shares of the biopharmaceutical company’s stock valued at $317,000 after purchasing an additional 10,250 shares during the last quarter. Finally, Choreo LLC bought a new stake in shares of Affimed in the 2nd quarter worth approximately $54,000. 30.82% of the stock is currently owned by hedge funds and other institutional investors.

About Affimed

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company’s lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid.